A phenotypic screening platform for chronic pain therapeutics using all-optical electrophysiology
Authors:
- 14 November 2023
- journal article
- research article
- Published by Wolters Kluwer Health in Pain
- Vol. 165 (4) , 922-940
Abstract
Chronic pain associated with osteoarthritis (OA) remains an intractable problem with few effective treatment options. New approaches are needed to model the disease biology and to drive discovery of therapeutics. We present an in vitro model of OA pain, where dorsal root ganglion (DRG) sensory neurons were sensitized by a defined mixture of disease-relevant inflammatory mediators, here called Sensitizing PAin Reagent Composition or SPARC. Osteoarthritis-SPARC components showed synergistic or additive effects when applied in combination and induced pain phenotypes in vivo. To measure the effect of OA-SPARC on neural firing in a scalable format, we used a custom system for high throughput all-optical electrophysiology. This system enabled light-based membrane voltage recordings from hundreds of neurons in parallel with single cell and single action potential resolution and a throughput of up to 500,000 neurons per day. A computational framework was developed to construct a multiparameter OA-SPARC neuronal phenotype and to quantitatively assess phenotype reversal by candidate pharmacology. We screened ∼3000 approved drugs and mechanistically focused compounds, yielding data from over 1.2 million individual neurons with detailed assessment of functional OA-SPARC phenotype rescue and orthogonal “off-target” effects. Analysis of confirmed hits revealed diverse potential analgesic mechanisms including ion channel modulators and other mechanisms including MEK inhibitors and tyrosine kinase modulators. Our results suggest that the Raf-MEK-ERK axis in DRG neurons may integrate the inputs from multiple upstream inflammatory mediators found in osteoarthritis patient joints, and MAPK pathway activation in DRG neurons may contribute to chronic pain in patients with osteoarthritis.Keywords
All Related Versions
Funding Information
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R44AR074820)
This publication has 122 references indexed in Scilit:
- HDAC inhibitors attenuate the development of hypersensitivity in models of neuropathic painPain, 2013
- Gain-of-function Na v 1.8 mutations in painful neuropathyProceedings of the National Academy of Sciences of the United States of America, 2012
- Selective inhibition of extracellular signal-regulated kinases 1/2 blocks nerve growth factor to brain-derived neurotrophic factor signaling and suppresses the development of and reverses already established pain behavior in ratsNeuroscience, 2012
- Discovery, Synthesis, and Structure–Activity Relationship of a Series of N-Aryl-bicyclo[2.2.1]heptane-2-carboxamides: Characterization of ML213 as a Novel KCNQ2 and KCNQ4 Potassium Channel OpenerACS Chemical Neuroscience, 2011
- Cellular and Molecular Mechanisms of PainCell, 2009
- Automated Analysis of Cellular Signals from Large-Scale Calcium Imaging DataNeuron, 2009
- Mitogen-activated protein kinases as therapeutic targets in osteoarthritisCurrent Opinion in Rheumatology, 2008
- Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part IArthritis & Rheumatism, 2007
- A-803467, a potent and selective Na v 1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the ratProceedings of the National Academy of Sciences, 2007
- Identification of the α2-δ-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalinProceedings of the National Academy of Sciences, 2006